L-Asgen plays a vital role in the treatment of ALL and certain lymphomas, offering a targeted approach to cancer therapy. Its use requires careful administration and vigilant monitoring to manage potential side effects and maximize therapeutic outcomes.

Indications:

• Acute Lymphoblastic Leukemia (ALL):
  Often used as part of a combination chemotherapy regimen.
• Lymphoblastic Lymphoma (off-label):
  In select cases, to inhibit tumor growth in asparagine-dependent cancers.

L-Asgen hydrolyzes the amino acid asparagine into aspartic acid and ammonia. Normal cells can synthesize asparagine; however, leukemia cells lack this ability. By depleting extracellular asparagine, L-Asgen effectively starves leukemia cells, leading to their apoptosis.